The US-based Watson Pharma announced that it has acquired its Swiss competitor, Actavis. Both Watson and Actavis have operations in India.
The combined company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland. The combined entity will have an anticipated 2012 revenues in excess of $8 billion, says a press release from Watson.
In April, Watson acquired the Mumbai-based Sekhsaria Chemicals. Watson also has a manufacturing facility in Goa.
Actavis has been in India since it opened a sourcing office in 2001. It has a bulk drug manufacturing plant at Alathur, near Chennai. In addition, the Actavis Pharma Development Centre operates a Stability Testing and Development laboratory located at TICEL BIO Park, Chennai and conducts highly competent Post-Marketing Stability Control Studies for EU products. This recognised EOU has been successfully inspected by USFDA in 2011.